Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline. 

overflowing coffee cup with coffee spilled on table
While greater than proportional enrollment may be necessary, the FDA will not conduct statistical testing on population subgroups. • Source: Shutterstock

Drug and medical device sponsors may need to overenroll key patient populations under the US Food and Drug Administration’s new diversity action plan guidance, a move that could make the revamped clinical trial diversity push more challenging than anticipated.

Key Takeaways
  • Aiming high for diversity, the FDA says greater than proportional enrollment for some subpopulations may be warranted as targets in soon-to-be required diversity action plans, but says it would not do statistical testing on population subgroups.

The 2022 Food and Drug Omnibus Reform Act (FDORA) implemented a requirement for sponsors to submit “diversity action plans” for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

Haleon Study: Boosting Health Literacy Could Save Major Economies Over $300bn Per Year

 
• By 

By addressing disparities in health literacy, particularly in the areas of oral care, bone health, nutrition and air pollution, the consumer health industry can “save lives and billions in healthcare costs, boosting productivity and increasing GDP,” says a new report from Haleon and Economist Impact.

Bayer Study: Self-Care Is Hardest For Those Who Need It Most

 
• By 

Being poor makes it more likely that you will suffer from self-treatable health conditions but it also means you will find it harder to take advantage of self-care solutions, finds a recently-published study by Bayer Consumer Health and IQVIA.

Beauty Deserts, People With Disabilities, Hormonal Health: FIT Grads On Inclusivity Gaps

 
• By 

The Fashion Institute of Technology’s “Beauty Think Tank” provides findings from six months of consumer research to “help guide organizations through the evolving landscape of beauty and accessibility.”

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

 
• By 

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

More from ESG

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By 

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By 

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By 

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”